ClinicalTrials.gg
CompletedNCT01787279Updated Jul 22, 2016Results posted

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

A Phase 4 interventional study of Peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 4 sites in Morocco. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-07-22.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
44th of 59
59 · median 114
Started
2006
with 4 others
Phase 4
29 of 59
none open now
Registered
34th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 44th largest by enrollment, is one of 5 that started in 2006, is one of 29 in phase 4, and was the 34th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys 180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during treatment and for 24 weeks of follow-up.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 and \</= 70 years of age
  • HBeAg-negative chronic
  • HBsAg-positive for at least 6 months, anti- hepatitis B (HBs) negative
  • Serum (ALT) > 2 (upper limit of normal) but \</= 10 x Upper limit of normal (ULN)
  • Hepatitis B virus (HBV) DNA > 10'000 copies/ml (Roche Monitor or Taqman)
  • No previous treatment with interferon (standard or pegylated) or with a nucleoside analogue
  • Women of must agree to use reliable during the study and for 3 months after treatment completion

Exclusion criteria

Exclusion Criteria:

  • Previous antiviral interferon-based therapy for chronic
  • Pregnant and lactating women
  • Evidence of decompensated liver disease
  • Co-infection with active hepatitis A, , hepatitis D and/or (HIV)
  • History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis
  • Previous or current hepatocellular carcinoma
  • History or other evidence of bleeding from oesophageal varices or other conditions consistent with decompensated liver disease
  • Inadequate hematologic or renal function
  • Serum level > 2 times the
  • Severe psychiatric disease
  • History of severe seizure disorder or current anticonvulsant use
  • History of evidence of any disease or condition which would make the patient, in the opinion of the investigator, unsuitable for the study
  • Evidence of drug abuse within one year of study entry
  • Alcohol intake of more than 3 standard drinks per day for men and 2 standard drinks per day for women (1 standard drink contains 10 g of alcohol)
  • Participation in another trial or receipt of an drug within 12 weeks prior to screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Peginterferon alpha-2a, 180 mcg/48 weeks

    Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.

    Drug: Peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72

    Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (at Week 72) were reported.

    Time frame: At Week 72

  2. Percentage of Participants Achieving Normalization of Alanine Aminotransferase at Week 72

    Percentage of participants with a normal serum alanine aminotransferase (ALT) level at the end of the study was analyzed. Normal ranges for ALT are 7 to 56 International Units/Litre. Participants with ALT less than the upper limit of normal at end of treatment were reported.

    Time frame: At Week 72

  3. Number of Participants With Any Adverse Events and Serious Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above

    Time frame: Up to Week 72

Secondary outcomes

  1. Percentage of Participants Achieving Hepatitis B Virus DNA < 400 Copies/mL at Week 72

    Participants who had HBV-DNA levels below 400 Copies/mL at the end of follow-up (at Week 72) were reported.

    Time frame: At Week 72

  2. Percentage of Participants Achieving Hepatitis B Surface Antigen Seroconversion at Screening and Week 48

    Seroconversion is defined as the absence of hepatitis B surface antigen (HBsAg) with a negative result for HBsAg and the presence of anti-Haemoglobin (HBs) antibodies (a positive result for anti-HBs) determined at Week 48. Blood samples were analyzed to check whether it is HBsAg-negative and anti-HBs antibodies positive.

    Time frame: At Screening and Week 48

  3. Percentage of Participants Achieving Combined Response Hepatitis B Virus DNA < 10,000 Copies/mL and Normal ALT at Week 72

    Percentage of participants showing normal ALT values and HBV DNA levels \<10,000 copies/ mL were reported.

    Time frame: At Week 72

07

Results

Posted Jul 22, 2016

Participant flow

A total of 59 participants were enrolled in this study conducted from 13 January 2006 to 25 May 2009 at 9 centers in Kingdom of Morocco.

Participant flow — Overall Study
MilestonePeginterferon Alpha-2a, 180 mcg/48 Weeks
Started59
Completed56
Not completed3
Withdrew: Lost to follow-up2
Withdrew: Lack of efficacy1

Outcome measures

PrimaryPercentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72

Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (at Week 72) were reported.

Time frame:
At Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72
Percentage of participantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 7265.4 (52.5 to 78.3)
PrimaryPercentage of Participants Achieving Normalization of Alanine Aminotransferase at Week 72

Percentage of participants with a normal serum alanine aminotransferase (ALT) level at the end of the study was analyzed. Normal ranges for ALT are 7 to 56 International Units/Litre. Participants with ALT less than the upper limit of normal at end of treatment were reported.

Time frame:
At Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Normalization of Alanine Aminotransferase at Week 72
Percentage of participantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
Percentage of Participants Achieving Normalization of Alanine Aminotransferase at Week 7268.6 (56.8 to 80.4)
PrimaryNumber of Participants With Any Adverse Events and Serious Adverse Events

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above

Time frame:
Up to Week 72
Reported as:
Number · Participants
Number of Participants With Any Adverse Events and Serious Adverse Events
ParticipantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
Any AE46
Any SAE0
SecondaryPercentage of Participants Achieving Hepatitis B Virus DNA < 400 Copies/mL at Week 72

Participants who had HBV-DNA levels below 400 Copies/mL at the end of follow-up (at Week 72) were reported.

Time frame:
At Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Hepatitis B Virus DNA < 400 Copies/mL at Week 72
Percentage of participantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
Percentage of Participants Achieving Hepatitis B Virus DNA < 400 Copies/mL at Week 7226.9 (14.8 to 39.0)
SecondaryPercentage of Participants Achieving Hepatitis B Surface Antigen Seroconversion at Screening and Week 48

Seroconversion is defined as the absence of hepatitis B surface antigen (HBsAg) with a negative result for HBsAg and the presence of anti-Haemoglobin (HBs) antibodies (a positive result for anti-HBs) determined at Week 48. Blood samples were analyzed to check whether it is HBsAg-negative and anti-HBs antibodies positive.

Time frame:
At Screening and Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Hepatitis B Surface Antigen Seroconversion at Screening and Week 48
Percentage of participantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
HBs-Ag Negative, Screening (n= 59)1.7
HBs-Ag Negative, Week 48 (n= 55)10.9
Anti-HBs Positive, Screening (n= 59)0
Anti-HBs Positive, Week 48 (n= 55)10.9
SecondaryPercentage of Participants Achieving Combined Response Hepatitis B Virus DNA < 10,000 Copies/mL and Normal ALT at Week 72

Percentage of participants showing normal ALT values and HBV DNA levels \<10,000 copies/ mL were reported.

Time frame:
At Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Combined Response Hepatitis B Virus DNA < 10,000 Copies/mL and Normal ALT at Week 72
Percentage of participantsPeginterferon Alpha-2a, 180 mcg/48 Weeks
Percentage of Participants Achieving Combined Response Hepatitis B Virus DNA < 10,000 Copies/mL and Normal ALT at Week 7258.8

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alpha-2a, 180 mcg/ 48 Weeks—0/59 (0%)40/59 (67.8%)
Most frequent other events
Most frequent other events
EventPeginterferon Alpha-2a, 180 mcg/ 48 Weeks
AstheniaGeneral disorders23/59
NeutropeniaBlood and lymphatic system disorders9/59
InsomniaPsychiatric disorders7/59
AnxietyPsychiatric disorders5/59
ArthralgiaGeneral disorders4/59
MyalgiaMusculoskeletal and connective tissue disorders4/59

Baseline characteristics

Safety analysis population included all the participants who received at least one dose of study medication and have one subsequent post baseline safety assessment

Age, Continuous
Age, Continuous(years)Peginterferon Alpha-2a, 180 mcg/48 Weeks
Mean41 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alpha-2a, 180 mcg/48 Weeks
Female12
Male47
08

Study locations

4 sites
  • Casablanca, 20100, Morocco
  • Casablanca, Morocco
  • Rabat, 504, Morocco
  • Rabat, 62000, Morocco
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2013
First posted
Feb 8, 2013
Start
Jan 2006
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jul 22, 2016
Last update
Jul 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01787279
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 8, 2013
Start date
Jan 2006
Primary completion
May 2009
Completion
May 2009
Results posted
Jul 22, 2016
Last update
Jul 22, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion